NexGen Sequencing for precision powered decisions

Personalising genomics for cancer treatment.

Personalising genomics for cancer treatment.

AI/ML (iCore) enabled dynamic data analysis

Reporting through ‘Indx Knowledge Base (iKB)’.

OncoIndx™ offers comprehensive genomic profiling across solid tumours. Its unique design identifies key actionable insights for personalising cancer treatment.

OncoIndx in practice

  • Challenges of managing complex cancers areaddressed through evidence-based choice of medication.

  • NGS report enhanced with artificial intelligence and updated clinical studies help identify the most beneficial therapeutic options.

  • An easy digital interface to interpret and understand complex cancer genomics.

Where is OncoIndx needed?

  • Cancers progressing on standard-of-care treatment

  • Cancers where personalised treatment could enhance survival

  • Cancers showing resistance to conventional treatment.

  • Cancers where combination of target drugs and/ or immunotherapy could benefit.

Designed for oncologists managing complex, advanced and refractory cancer patients.

  • Proprietary panel of 1,000+ genes

  • Longitudinal monitoring markers

  • PD-L1 through IHC (TBx) / immunofluorescence on CTCs (LBx)

  • CTC enumeration

  • Traceability to ongoing clinical trials worldwide

Review of genomic results by scientific board leading to pertinent treatment decisions.

Key actionable genes included:

Features of the OncoIndx® Test Report

  • In accordance to international guidelines.

  • Clear, unambiguous and actionable genomic findings.

  • Based on highly reliable and internally curated databases.

OncoIndx is a well-validated NGS test to extract therapy information from tumor DNA. It is possible on both tissue as well as blood sample.

This NGS test includes 1000+ genes of targetable/ therapeutic significance.

1000+ genes

>99% on target coverage

The test has a mean coverage of 98-100% across all tested genes.

The test is performed at a mean depth of 2000x for tissue samples and 10000x for blood.

2000x / 10000x mean depth

Technical specification

FAQs for Patients

  • OncoIndx is a comprehensive genomic profiling (CGP) that analyzes the entire genome or a large portion of it to identify genetic mutations or changes that may be driving a person's cancer.

  • It can be used to identify genetic changes or mutations in a variety of cancer types, including the most common ones like breast, lung, colon, pancreatic, and ovarian cancer etc.

  • OncoIndx test can be performed on both tissues (fresh or FFPE) and blood for liquid biopsy samples

  • 2 tubes of 10 ml of blood in PAXgene tube/ Streck tube are needed for OncoIndx testing

  • Ideally, one week of washout period is required if the patient is under therapy e.g. Chemotherapy, Immunotherapy, etc.

  • It is not typically used to diagnose cancer, but it can be used to identify genetic changes or mutations that may be driving cancer. This information can help guide treatment decisions and identify potential targeted therapies.

  • We intend to expand OncoIndx to various other fluids like cerebrospinal fluid in the future, but currently, we perform this only in whole blood samples

  • 12 days

  • 1000+ genes. 1080 to be precise

  • It is not covered under any special scheme of insurance but if the company covers genomic testing, this will also be subjected to their scrutiny

  • There are no known risks associated with this test. The test is performed using a small sample of tumor tissue and peripheral blood and the risk of complications is low.

  • We will report all the mutations identified in the patient. However, the oncologist will decide treatment regimen based on the patient's age and overall condition

  • OncoIndx is both a liquid as well as solid tumor-based test

  • You can order a test by calling us by phone or by sending an email

  • Yes, OncoIndx can be ordered for paediatric patients

  • VUS referred to a variant with unknown significance. If OncoIndx reports VUS, it means that regular monitoring of the individual might be required to protect against any future occurrences of pathogenic alterations

  • We follow our standard operating procedures (SOP) for each step involved in OncoIndx. For instance, we strongly recommend the usage of the designated paxgene tubes for blood collection and storage at specified conditions. Maintaining the recommended SOP can improve the quality of test outcomes.

FAQs for Oncologists

  • OncoIndx can detect alterations including point mutations/single nucleotide variations, copy number variations, microsatellite instability (MSI) and tumor mutational burden (TMB)

  • Yes

  • Hybridization capture (Illumina based)

  • OncoIndx test provides an average depth of 1000x for tissue biopsy and 5000x for liquid biopsy.

  • No, OneCellDx works using a specific in-house technique which requires blood collection in heparinized tubes

  • Yes, OncoIndx predicts sensitivity to chemotherapeutic drugs by detecting the mutational statuses of genes like TP53, UGT1A1, etc.

  • SNVs and indels: 0.1% (~99% accuracy), Amplification: 1% (>95% accuracy), Fusions: 5% cutoff (>90% accuracy)

  • OncoIndx is a more comprehensive and in-depth genomic test compared to other tests, such as gene panel testing, which only analyzes a specific set of genes. This test analyzes the entire genome or a large portion of it, providing a more complete picture of a person's cancer.

  • It covers 1000 genes in the test

  • Yes, patients can be recommended OncoIndx even during stable disease as this test will validate the genetic basis of the disease condition and also investigate other emerging mutations if any at an early stage to avoid serious consequences of recurrent disease

  • There are no known risks associated with this test. The test is performed using a small sample of tumor tissue and peripheral blood and the risk of complications is low.

  • Results are analysed using Artificial Intelligence (AI) and machine learning (ML) algorithm

  • This test can provide information about the genetic changes present in a person's cancer, which may help predict their cancer prognosis. However, other factors, such as the stage and grade of cancer, are also important in predicting prognosis.

  • Delays can happen in multiple areas like sample processing, data analysis, report generation, etc. But we assure delivery within TAT as we calculated the chances of delays in the specified TAT

  • Ideally, one week of washout period is required if the patient is under therapy e.g. Chemotherapy, Immunotherapy, etc.

  • MSI is determined by looking around MSI-prone regions across all targeted regions covered in OncoIndx. Yes

  • Yes, the OncoIndx test can evaluate tumor mutational burden (TMB) score

  • Under process (DCGI)

  • Oncoindx is an RUO product, FDA approval will be done soon

  • Yes, OncoIndx can be ordered for paediatric patients

  • Yes, since we cover the entire ALK gene, OncoIndx will be able to detect resistance mutations in ALK

  • VUS referred to a variant with unknown significance. If OncoIndx reports VUS, it means that regular monitoring of the individual might be required to protect against any future occurrences of pathogenic alterations

  • We follow our standard operating procedures (SOP) for each step involved in OncoIndx. For instance, we strongly recommend the usage of the designated streck tubes for blood collection and storage at specified conditions. Maintaining the recommended SOP can improve the quality of test outcomes.

  • cfDNA may not reduce as a response to the drug rather we might observe a difference/variation in ctDNA since they are specific to tumor cells

  • Yes. In such cases, we will get in touch with you for evaluating the DNA quality and if it matches our range, we will accept your DNA sample for OncoIndx testing

  • Ideally, one week of washout period is required if the patient is under therapy e.g. Chemotherapy, Immunotherapy, etc.